ADC Therapeutics

80 articles with ADC Therapeutics

• ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event

  1/4/2021

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Acce

• ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures

  12/15/2020

   M.S.Q. Ventures ("MSQ") is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT BioPharma (CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital. 

• ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting

  12/7/2020

  LOTIS 3 interim results highlight potential of Lonca in combination with ibrutinib in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma patients

• 

  After FDA Grants Priority Review, ADC Therapeutics Gets One Step Closer to Bringing B-Cell Lympho...

  11/20/2020

  The U.S. Food and Drug Administration has accepted ADC Therapeutics’ Biologics License Application (BLA) and granted priority review for the company’s relapsed/refractory diffuse large B-cell lymphoma (DLBCL) treatment, loncastuximab tesirine (Lonca).

• ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights

  11/12/2020

  - Submitted BLA for lead program, Lonca, for treatment of relapsed or refractory DLBCL on September 21, 2020 - Commercial launch activities on track for potential U.S. launch of Lonca in mid-2021 - Initiated Phase 3 confirmatory trial of Lonca in combination with rituximab in second-line DLBCL - Strong balance sheet with $494 million in cash and cash equivalents as of September 30, 2020

• ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

  11/10/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on Novem

• ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

  11/5/2020

  ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

• ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting

  11/4/2020

  ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62 nd American Society of Hematology Annual Meeting Several presentations highlight lead candidate loncastuximab tesirine (Lonca); BLA under FDA review for the treatment of relapsed or refractory diffuse large B-cell lymphoma

• ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

  11/3/2020

  ADC Therapeutics SA (NYSE: ADCT), today announced that the first patient has been dosed with camidanlumab tesirine (Cami, formerly ADCT-301) in combination with pembrolizumab, a checkpoint inhibitor, in an ongoing Phase 1b clinical trial in patients with selected advanced solid tumors.

• ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

  10/9/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the underwriters in its recent upsized public offering of 6,000,000 common shares, which closed on September 28, 2020, have exercised in full

• New Ventures Funds Rebrands as Scientia Ventures

  10/2/2020

  New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.

• ADC Therapeutics Announces Pricing of Public Offering

  9/24/2020

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the pricing of an upsized public offering of 6,000,000 shares of its common shares at a price of $34.00 per share.

• ADC Therapeutics Announces Proposed Public Offering

  9/21/2020

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commencement of a proposed underwritten public offering of 5,500,000 shares of its common shares. Certain existing shareholders expect t

• ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

  9/21/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (B

• ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020

  9/17/2020

  Preliminary pharmacokinetic and biomarker data support continued evaluation of Cami as a novel immuno-oncology approach for patients with solid tumor cancers LAUSANNE, Switzerland--( BUSINESS WIRE )-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies

• ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers

  9/10/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hem

• ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131

  9/5/2020

  ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc., the lead book-running managers in the Company’s recent initial public offering, are releasing a lock-up restriction with respect to 105,000 common shares held by A.T. Holdings II Sàrl, an affiliate of Peter B. Corr and Stephen Evans-Freke who are members of the Company’s board of directors, as part of a

• ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights

  8/18/2020

  On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing

• ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020

  8/12/2020

  ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020

• Synaffix Announces Expansion of Collaboration with ADC Therapeutics

  7/23/2020

  Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies.